[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Neurocrine Bioscienc (NBIX)

Neurocrine Bioscienc (NBIX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Neurocrine Bioscienc 6027 Edgewood Bend Court San Diego CA 92130 USA

www.neurocrine.com Employees: 2,000 P: 858-617-7600

Sector:

Medical

Description:

Neurocrine Biosciences is a neuroscience-based company focused on the discovery and development of novel therapeutics for neuropsychiatric, neuroinflammatory and neurodegenerative diseases and disorders. The company's neuroscience, endocrine and immunology disciplines provide a unique biological understanding of the molecular interaction between central nervous, immune and endocrine systems for the development of therapeutic interventions for anxiety, depression, insomnia, stroke, malignant brain tumors, multiple sclerosis, obesity and diabetes.

Key Statistics

Overview:

Market Capitalization, $K 18,178,436
Enterprise Value, $K 17,465,436
Shares Outstanding, K 100,550
Float, K 95,925
% Float 95.40%
Short Interest, K 5,335
Short Float 5.31%
Days to Cover 4.91
Short Volume Ratio 0.76
% of Insider Shareholders 4.60%
% of Institutional Shareholders 92.59%

Financials:

Annual Sales, $ 2,861 M
Annual Net Income, $ 478,600 K
Last Quarter Sales, $ 814,500 K
Last Quarter Net Income, $ 197,900 K
EBIT, $ 788,900 K
EBITDA, $ 806,300 K

Growth:

1-Year Return 35.64%
3-Year Return 77.89%
5-Year Return 101.84%
5-Year Revenue Growth 173.50%
5-Year Earnings Growth 13.22%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 1.94 on 05/05/26
Next Earnings Date 07/30/26 [AMC]
Earnings Per Share ttm 5.94
EPS Growth vs. Prev Qtr -1.40%
EPS Growth vs. Prev Year 1,662.50%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payable Date 12/31/69
Dividend Payout Ratio 0.00%

NBIX Ratios

Ratio
Price/Earnings ttm 30.78
Price/Earnings forward 25.71
Price/Earnings to Growth 0.77
Return-on-Equity % 19.79%
Return-on-Assets % 13.82%
Profit Margin % 16.73%
Debt/Equity 0.00
Price/Sales 6.43
Price/Cash Flow 36.48
Price/Book 5.40
Book Value/Share 33.89
Interest Coverage -1.61
60-Month Beta 0.39
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.